[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-340217-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-340217-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","micro-rnas-in-breast-cancer-progression-and-metastasis-a-chromatin-and-metabolic-perspective","Micro-RNAs in breast cancer progression and metastasis - A chromatin and metabolic perspective","","Breast cancer is a highly complex disease with multiple subtypes. Genomic integrity is regulated by mechanisms such as DNA damage machinery and mitotic checkpoints, and defects in key regulatory genes can drive genomic instability and malignancy. Dysregulated coding and noncoding gene expression follows. Long noncoding RNAs and microRNAs (miRNAs) act as central regulators of cancer gene networks. Specific miRNAs can modulate heterochromatin-associated proteins, remodel chromatin accessibility, and promote oncogenic programs. They may also enhance progression and metastasis by shaping a metabolic microenvironment supporting tumor growth.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/micro-rnas-in-breast-cancer-progression-and-metastasis-a-chromatin-and-metabolic-perspective/340217/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/micro-rnas-in-breast-cancer-progression-and-metastasis-a-chromatin-and-metabolic-perspective/340217.png","ImageObject",300,407,{"name":42,"@type":43},"River Wang","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-01","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"How do microRNAs influence chromatin in breast cancer?","Question",{"text":63,"@type":64},"Some miRNAs repress heterochromatin-associated proteins, inducing open chromatin and promoting gene expression required for oncogenesis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"What roles can miRNAs play in breast cancer progression and metastasis?",{"text":68,"@type":64},"Specific miRNAs may favor progression and metastasis by regulating genes that support the metabolic microenvironment essential for cancer cell growth and proliferation.",{"name":70,"@type":61,"acceptedAnswer":71},"Why is targeting dysregulated noncoding RNAs considered a potential therapy?",{"text":72,"@type":64},"Because lncRNAs and miRNAs contribute to breast cancer development through dysregulated activity, understanding their mechanisms can open therapeutic avenues for intervention.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},340217,1790310938,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":109,"preview_page_count":33,"preview_urls":145},1099514067438,"https://ap-avatar.wpscdn.com/avatar/100002539ee87300030?x-image-process=image/resize,m_fixed,w_180,h_180&k=1780474512215547542","Heliyon 10 (2024) e38193  \nContents lists available at ScienceDirect  \nHeliyon  \njournal [homepage:](homepage: www.cell.com/heliyon)[ www.cell.com/heliyon](homepage: www.cell.com/heliyon)  \n| Review article\u003Cbr>Micro-RNAs in breast cancer progression and metastasis: A chromatin and metabolic perspective\u003Cbr>Sweta Sikdera,1, Aditya Bhattacharya a,1, Aayushi Agrawalb,d, Gautam Sethic, Tapas K. Kundu a,*\u003Cbr>a Transcription and Disease Laboratory, Molecular Biology and Genetics Unit, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, 560064, India\u003Cbr>b Division of Cancer Biology, CSIR-Central Drug Research Institute, Sector-10, Jankipuram Extension, Sitapur Road, Lucknow, 226031, UP, India c Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore, 16 Medical Drive, 117600, Singapore d Academy of Scientific and Innovative Research, Ghaziabad, Uttar Pradesh, 201002, India |\n| --- |\n| A B S T R A C T |\n| Breast cancer is a highly complex disease with multiple subtypes. While many of the breast cancer cases are sporadic some can be familial or hereditary. Genomic integrity is closely monitored by several mechanisms, such as DNA damage machinery and mitotic checkpoints. Any defect in the key genes involved in the regulation of these mechanisms often results in genomic instability, predisposing the cells to malignancy. This results in altered expression of many coding and noncoding genes. The noncoding RNAs especially the long noncoding RNA (lncRNAs) and microRNA (miRNAs) act as key regulators of cancer gene networks. Some miRNAs repress the expression of the heterochromatin-associated proteins, inducing the formation of open chromatin, and promoting the expression of genes required for oncogenesis. Additionally, specific miRNAs may also favour cancer progression and metastasis by regulating the expression of genes that support the metabolic microenvironment essential for cancer cell growth and proliferation. Understanding how these noncoding RNAs contribute to breast cancer development opens potential avenues for therapeutic intervention, targeting their dysregulated activity. |\n\n1. Introduction  \nBreast cancer is the most prevalent form of non-cutaneous cancer affecting women all over the world [1]. Due to the inherent heterogeneity of breast tumours, there are ongoing concerns in terms of accurate diagnosis and effective therapeutics. In recent years, advancements in imaging techniques have allowed for earlier detection of breast cancer, which has led to a reduction in mortality ratesand disease burden within the general population. However, despite these improvements, breast cancer remains a formidable threat due to its ability to progress to advanced stages and develop resistance to radiation therapy and chemotherapy. The development of malignant tumour in breast tissues, mainly the ducts and lobules responsible for milk secretion results in breast cancer. Although extensive research in the field has shed light on the molecular pathways and gene expression patterns in breast tumours, the exact cause of breast cancer in most patients remains an enigma. Various risk factors contribute to the development of breast carcinoma. These include age, family background, obesity, excessive alcohol consumption, exposure to estrogen, and inherited defects such as mutations in susceptibility genes like BRCA1 and BRCA2 [2]. Women harbouring the BRCA mutation in their genome are estimated to carry a 40 %–85 % risk of developing breast cancer, ovarian cancer as well as other primary cancers. BRCA1 and BRCA2, located on chromosomes 17 and 13, respectively are inherited in an autosomal dominant fashion with high penetrance, thus increasing the  \n* Corresponding author.  \nE-mail address: [tapas@jncasr.ac.in](tapas@jncasr.ac.in) (T.K. Kundu).  \n1 These authors contributed equally.  \n[https://doi.org/10.1016/j.heliyon.2024.e38193](https://doi.org/10.1016/j.heliyon.2024.e38193)  \nReceived 2 April 2024;","cbCaimcJLANi8k3Y","https://ap.wps.com/l/cbCaimcJLANi8k3Y","pdf",5480032,16,"English","# Introduction\n## Breast cancer risk factors and heterogeneity\n# Genomic integrity and noncoding RNA regulation\n## microRNA control of chromatin-associated programs\n## miRNA roles in metabolic microenvironments\n# Therapeutic implications","[{\"question\":\"How do microRNAs influence chromatin in breast cancer?\",\"answer\":\"Some miRNAs repress heterochromatin-associated proteins, inducing open chromatin and promoting gene expression required for oncogenesis.\"},{\"question\":\"What roles can miRNAs play in breast cancer progression and metastasis?\",\"answer\":\"Specific miRNAs may favor progression and metastasis by regulating genes that support the metabolic microenvironment essential for cancer cell growth and proliferation.\"},{\"question\":\"Why is targeting dysregulated noncoding RNAs considered a potential therapy?\",\"answer\":\"Because lncRNAs and miRNAs contribute to breast cancer development through dysregulated activity, understanding their mechanisms can open therapeutic avenues for intervention.\"}]","Micro-RNAs in breast cancer progression and metastasis - A chromatin and metabolic perspective | PDF",1790034991,[146,150,154,158],{"page_no":22,"url":147,"width":148,"height":149},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/27f1e5f33568fba27dcf05db1533b7ff.webp",983,1341,{"page_no":26,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/11e3d68bfad956c1b809d8a111233e6d.webp",982,1340,{"page_no":30,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/fdff5d0d50f598311a9f152063576da4.webp",981,1338,{"page_no":33,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ffe6e96f5e8994c7f30c387e04d9c87c.webp",980,1337]